On January 24, 2019 Ribon Therapeutics, a clinical stage biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions, reported it will be presenting at two upcoming scientific conferences (Press release, Ribon Therapeutics, JAN 24, 2020, View Source [SID1234553520]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
PARP & DDR Inhibitors Summit
Jan. 28-30, 2020
Location: Revere Hotel, Boston, MA
Presentation: Not all PARPs are Alike: Exploring the Therapeutic Potential of PARPi Beyond PARP1 Inhibitors
Speaker: Heike Keilhack, SVP of Biological Sciences
Time: 10am ET, Wednesday, Jan. 29
SLAS 2020 International Conference and Exhibition
Jan. 25-29, 2020
Location: San Diego Convention Center, San Diego, CA
Podium presentation: A Bespoke Screening Platform to Study mono(ADP-ribosylation)
Speaker: Tim Wigle, Director, Molecular Discovery Group
Time: 2:30pm PT, Wednesday, Jan. 29
Poster presentation: Development of Novel Biochemical Assays for the Screening of MonoPARP Enzymes
Speaker: Dave Church, Sr. Research Associate, Molecular Discovery Group
Time: 5:00pm PT, Tuesday, Jan. 28